Acadia Investigates Nuplazid (Pimavanserin) Therapy to Treat Psychosis in Alzheimer’s Patients

Acadia Investigates Nuplazid (Pimavanserin) Therapy to Treat Psychosis in Alzheimer’s Patients
Acadia Pharmaceuticals plans to start a Phase 3 clinical program to explore the effect of Nuplazid (pimavanserin) in Alzheimer’s disease patients with psychosis. The medication was approved by the U.S. Food and Drug Administration in April 2016 to treat similar problems with Parkinson's patients. “We’re very pleased with our strong start to 2017,” Acadia President and CEO Steve Davis said in a news release that also reported the company's net revenue for the first quarter of 2017 at $15.3 million, a 28 percent increase from the fourth quarter of 2016.“We continue to advance our ongoing clinical studies in Alzheimer’s disease agitation, schizophrenia inadequate response, schizophrenia negative symptoms and major depressive disorder, and we look forward to moving our Alzheimer’s disease psychosis program into Phase III in the second half of 2017.” Acadia, based in San Diego, has two ongoing trials for pimavanserin. The first, NCT03118947 is now recruiting patients to assess the drug's safety and tolerability  over 52 weeks of treatment in more than 400 patients with probable Alzheimer’s who have symptoms of agitation and aggression. The trial will likely end in 2020. The SERENE trial (NCT02992132) is also recruiting patients and will evaluate the efficacy of pimavanserin to treat agitation and aggression compared with placebo after
Subscribe or to access all post and page content.